Rare diseases specialist Swedish Orphan Biovitrum has appointed Anne Marie de Jonge Schuermans as head of its new Technical Operations organization, bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety operations.
Ms de Jonge Schuermans will join on October 1, 2018, and be part of Sobi’s Executive Committee. She joins Sobi from Biogen (Nasdaq: BIIB) where she served as vice president for global supply chain operations and strategic partnerships and as an executive board member of Biogen International GmbH.
Ms de Jonge Schuermans brings more than 15 years of experience in the healthcare industry from Biogen, Stryker and Novartis. She has a track record of putting processes and systems in place, and of driving transformation in cross-functional and cross-cultural settings.
Ms de Jonge Schuermans says: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space. I look forward to working with the teams to develop an effective and agile organization set for growth.”
Source: The Pharma Letter
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
